Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release its latest quarterly report later this week. Market watchers are anticipating strong performance driven by the robust sales of Lilly's blockbuster medications, particularly its insulin portfolio. However, there are also concerns about potential